Article Text
Statistics from Altmetric.com
Introduction
The burden of condyloma acuminata (CA) among under-represented groups has not been examined in a US-based epidemiological study. The new National Institutes of Health All of Us (AoU) Research Programme aims to gather health data from one million or more people living in the USA to elucidate health disparities, particularly in communities who have been historically excluded from biomedical research.1 Inclusion criteria are adults over 18 years with the capacity to consent.1 AoU defines under-represented groups prioritised for analysis based not only on race/ethnicity but also on age (≥75 years), disability (inability to perform everyday physical activities), sexual orientation/gender identity (lesbian, gay, bisexual, transgender, intersex, queer/questioning, asexual and all other non-heterosexual identities (LGBTQIA+)), income (annual household income ≤US$35 000) and education (less than a high-school degree).1 We used the latest AoU data release (available to registered researchers at www.researchallofus.org) to evaluate the disease burden of CA among under-represented groups defined by this novel framework.
Methods and results
We linked survey and electronic health record data to estimate the prevalence of CA on enrolment in each under-represented group. We evaluated AoU Registered …
Footnotes
Handling editor Anna Maria Geretti
Contributors IM came up with the data analysis plan and performed statistical analysis. All authors contributed to writing and revising the letter.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.